Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (359 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

359 publications

Pictilisib (GDC-0941) Chemical Structure

CAS No. 957054-30-7

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 359 publications

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Immunity, 2021, 54(8):1807-1824.e14

PubMed: 34380064 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5520

PubMed: 34535684 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Cell Rep, 2021, 35(11):109238

PubMed: 34133937 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

Int J Cancer, 2021, 10.1002/ijc.33594

PubMed: 33844847 ( click the link to review the publication )

Cancer Lett, 2021, 510:37-47

PubMed: 33872695 ( click the link to review the publication )
Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):741

PubMed: 34315868 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):619

PubMed: 34131114 ( click the link to review the publication )

Cell Oncol (Dordr), 2021, 10.1007/s13402-021-00628-7

PubMed: 34462871 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Biomolecules, 2021, 11(6)808

PubMed: 34072389 ( click the link to review the publication )

Front Oncol, 2021, 11:648985

PubMed: 34026624 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16889

PubMed: 34464509 ( click the link to review the publication )

Food Chem Toxicol, 2021, S0278-6915(21)00034-X

PubMed: 33484789 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):302

PubMed: 34107979 ( click the link to review the publication )

Phytomedicine, 2021, 92:153713

PubMed: 34479022 ( click the link to review the publication )

Cardiovasc Toxicol, 2021, 21(8):655-668

PubMed: 34021461 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 552:23-29

PubMed: 33740661 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Cancer Rep (Hoboken), 2021, e1459

PubMed: 34245130 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Mol Cell, 2020, 80(1):164-174.e4

PubMed: 32877642 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2020, 117(39):24427-24433

PubMed: 32929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31189-31197

PubMed: 33229547 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

ProQuest, 2020, N/A

PubMed: None ( click the link to review the publication )

JCI Insight, 2020, 5(22)141832

PubMed: 33048843 ( click the link to review the publication )
Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100016

PubMed: 32984851 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )
Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882967 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )
Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )
Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Physiol Rep, 2017, 5(18)e13441

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )
Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )
Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26384305 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )
Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )
J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )
Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	NFi2bFVMcW6jc3WgRZN{[Xl?		MlPVNUBp	M{LERWROW09?	MVLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGSnbIThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	NFnlOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	MYrLbY5ie2ViQYPzZZk>		MV2xJIg>	M{\1NmROW09?	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgTFExPDdvUjDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	NVrBPHlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
Sf9	NUPKXnpYU2mwYYPlJGF{e2G7		M2L4N\|EhcA>?	M13ZcmROW09?	NYHNOmdlUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEV3NEWtT{BufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	NEiyZ4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	M4\uOmtqdmG\|ZTDBd5NigQ>?		NV;hRYdXOSCq	MVPEUXNQ	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMEOzJO69VQ>?	NXK4[HZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
Sf9	MmjRT4lv[XOnIFHzd4F6		NIOybmEyKGh?	NEHvXJFFVVOR	MVXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjh	M1;3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
MDA-MB-361	NEHMeZBHfW6ldHnvckBCe3OjeR?=		M2f1OFIhcA>?	NU\hfHkyTE2VTx?=	NHmxNYpKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1\|NkGgZ4VtdHNid3n0bEBRUUt\|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{ODFOwG0>	M2ewflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
PC3	M4rjUmZ2dmO2aX;uJGF{e2G7		M2D1WFIhcA>?	MUfEUXNQ	M3zi[2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yM{eg{txO	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
U87MG	MknxSpVv[3Srb36gRZN{[Xl?		NIfIXnozKGh?	MoPySG1UVw>?	MYPJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNE[g{txO	NIfqd3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
MDA-MB-361	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXG5OkBp	Mnj5SG1UVw>?	M{\xfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvPzJizszN	MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NUS2OVQoRjF6N{W0OlU1RC:jPh?=
A2780	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NETYfIU6PiCq	MXvEUXNQ	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGy\|IIfpeIghWEmNM1PBJIFv\CCSVFXOJI12fGG2aX;uJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>?	NVn6U\|JjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
PC3	NXr6Xm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmrXPVYhcA>?	M{XoSGROW09?	M3GyZmlEPTB;MD6yPEDPxE1?	NWW3S4N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
U87MG	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NE\MZXY6PiCq	MVXEUXNQ	MkjoTWM2OD1yLkm1JO69VQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
Sf9	NVvac4FiU2mwYYPlJGF{e2G7		M{HORVMxKG2rbh?=	NFOyR3pFVVOR	MlnsTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	NX\oNm1SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFg{PDJpPkKyOVQ5OzR{PD;hQi=>
RAW 264.7	MULLbY5ie2ViQYPzZZk>		M4DXfFkxKG2rbh?=	M13oNGROW09?	M4LUZmlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvOjl6IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2OEO0Nkc,OjJ3NEizOFI9N2F-
Sf9	NXzCNY0{U2mwYYPlJGF{e2G7		M2DOfFEhcA>?		MVjJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW0Z7IHPlcIx{KHerdHigTWM2OCCxZjCwMlAyPyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2ME[0OUc,OjN3NEC2OFU9N2F-
Sf9	MojXT4lv[XOnIFHzd4F6		NU\W[4YxOSCq		MmO3TY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEC2OFUoRjJ\|NUSwOlQ2RC:jPh?=
Sf9	MmH2T4lv[XOnIFHzd4F6		NVTPO45yOSCq		NHfBXphKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\2GvbXGg[ZhxemW\|c3Xk	NVe4NIVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
Sf9	NXHaNZFRU2mwYYPlJGF{e2G7		MXKxJIg>		MV;Jcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm	NXvyOnp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
SKOV3	M{WxNWtqdmG\|ZTDBd5NigQ>?	MoXWNUDPxE1?	NYDxdoZFOSCq	M3\J[GROW09?	M2DX[mlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN4MEO0PEc,OjN\|NkCzOFg9N2F-
MCF7	NXXWS4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojUNUDPxE1?	MUC5OkBp	M2fkSWROW09?	NGPZPFVIUTVyPUCuNFcxOiEQvF2=	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NkCzOFgoRjJ\|M{[wN\|Q5RC:jPh?=
SKOV3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWexJO69VQ>?	MlXYPVYhcA>?	MVvEUXNQ	M4K3OGdKPTB;MD6xOFc3KM7:TR?=	NHvkPGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NFM1QCd-MkOzOlA{PDh:L3G+
PC3	M1rPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDKWGRYPzJiaB?=	MWjEUXNQ	MYHJR\|UxRTBwMkig{txO	M4DIN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUixO\|E1Lz5{MUm4NVcyPDxxYU6=
MCF7.1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NkBp	MoXLSG1UVw>?	NHHMV3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKEiHUkKg[4Vv\SC5aYToJGlEPTBib3[gNE4zQCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl6MUexOEc,OjF7OEG3NVQ9N2F-
MCF7-neo/Her2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYK3NkBp	M4e2d2ROW09?	M1TzU2lEPTB;MD6yPUDPxE1?	NUnVTpVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OlI6ODNpPkKzOlYzQTB\|PD;hQi=>
MCF7-neo/Her2	MWfLbY5ie2ViQYPzZZk>				MlXaTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25iYYSgV\|Q4OyC5aYToJGlEPTBib3[gNE4xODdizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4MkmwN{c,OjN4NkK5NFM9N2F-
PC3	NGfnTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{jMV\|czKGh?	MUnEUXNQ	MnLrSWM2OD1yLkO0JO69VQ>?	NGjZcJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OVY{QSd-MkG5PFU3Ozl:L3G+
MCF7.1	M2nYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHKdGJoPzJiaB?=	MlzQSG1UVw>?	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCHQ{WwJI9nKDBwM{mg{txO	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl6NU[zPUc,OjF7OEW2N\|k9N2F-
PC3	M1TubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fZNlczKGh?	M17WOWROW09?	M2e2S2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHTl[olkcWWwdDDpckBRXEWQIIfpeIghUUN3MDDv[kAxNjN7IN88US=>	NWS1R3pvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVA3PjlpPkKwNFUxPjZ7PD;hQi=>
MCF7.1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV23NkBp	NXL2NVU5TE2VTx?=	MorkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkO0JO69VQ>?	MkfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNUC2OlkoRjJyMEWwOlY6RC:jPh?=
MCF7.1	M1jHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp		M13ESGVEPTB;MD63NkDPxE1?	M2TuVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{S2OlU3Lz5{MEO0OlY2PjxxYU6=
NCI-H1975	NXjaemE4S3m2b4TvfIlkKEG\|c3H5		Mn36O\|IhcA>?		NX\RfJR3UUN3ME2wMlI4KM7:TR?=	NFXHU2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
H460	NUjYTWZKS3m2b4TvfIlkKEG\|c3H5		NGXrbZc4OiCq		NETlW29KSzVyPUCuPFch\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3OUW0OUc,OjNyNUm1OFU9N2F-
HT-29	NXjQS\|VjS3m2b4TvfIlkKEG\|c3H5		M1WxZ\|czKGh?		MXfJR\|UxRTBwNk[g{txO	MkXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNUm1OFUoRjJ\|MEW5OVQ2RC:jPh?=
HepG2	NWi4dnVHS3m2b4TvfIlkKEG\|c3H5		MYC3NkBp		MVrJR\|UxRTFizszN	M1z4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW5OVQ2Lz5{M{C1PVU1PTxxYU6=
SGC7901	MkPHR5l1d3SxeHnjJGF{e2G7		NXGySW1LPzJiaB?=		NXnvfFF2UUN3ME2xMlgh\|ryP	NWHqPW9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
NCI-H226	M4\rbGN6fG:2b4jpZ{BCe3OjeR?=		NXjZbW9ZPzJiaB?=		M{KzTGlEPTB;Mj65JO69VQ>?	NHrnOJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
A549	NFzyWG1EgXSxdH;4bYMhSXO\|YYm=		MWS3NkBp		M4HGeGlEPTB;Nj65JO69VQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3OUW0OUc,OjNyNUm1OFU9N2F-
U87MG	M1nGS2N6fG:2b4jpZ{BCe3OjeR?=		M3\JbVczKGh?		Ml63TWM2OD15Lke3JO69VQ>?	NUfmVZI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
HBC4	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULNNmlqdG:pR1m1NF0uPi5yMzDN	NGrOdpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
BSY1	M2n4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;Qfoxw\0eLNUC9MVYvQTBiTR?=	NHm3UHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HBC5	NYHUR5dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGycI9oT0l3ME2tOk43OCCP	Mn7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MCF7	M4riTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHsc4dIUTVyPT23MlM{KE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MDA-MB-231	NH3GcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTHUFBtd2eJSUWwQU02NjR4IF2=	NHvZZVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
U251	NXjqc2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfsc4dIUTVyPT21MlUxKE1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF268	NFSwdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLsc4dIUTVyPT21MlM6KE1?	Mn3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF295	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDsc4dIUTVyPT22MlM4KE1?	M2LWclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF539	NUnkWWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrORXJ{dG:pR1m1NF0uPi53MDDN	NHvtXnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB75	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrJOJR3dG:pR1m1NF0uPy5zMDDN	NFOzR4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB78	NY\vbZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjGRVFKdG:pR1m1NF0uPi53MjDN	M1fy[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCC2998	NX[0SGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPsc4dIUTVyPT22MlI6KE1?	Mn7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
KM12	NFrrRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnQOZJidG:pR1m1NF0uPS55NjDN	NX20VGpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HT-29	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDZcI9oT0l3ME2tOk4{OCCP	M4jrd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCT15	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nGSYxw\0eLNUC9MVYvOTJiTR?=	NWHLcWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCT116	M{\LNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;kO\|Ntd2eJSUWwQU02Njh5IF2=	NET6SpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H23	M1zSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3m3TYxw\0eLNUC9MVUvPzNiTR?=	NHjq[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H226	M2TsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2myeIxw\0eLNUC9MVYvOjFiTR?=	M{DKcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H522	M2fKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHsc4dIUTVyPT22MlU5KE1?	NHzFfnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H483	M4THUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Lqcoxw\0eLNUC9MVYvPTZiTR?=	NWi4Smp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
A549	M3vXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnmycI9oT0l3ME2tOk4yPSCP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
DMS273	NXXGWYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfsc4dIUTVyPT22MlQ{KE1?	M1v0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
DMS114	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnacI9oT0l3ME2tOU46OiCP	MlXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
LOXIMVI	M2fzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7mcpZtd2eJSUWwQU03NjJ7IF2=	NVW0SGpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLsc4dIUTVyPT22MlcyKE1?	NGC2NXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
OVCAR4	MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjqbXdtd2eJSUWwQU02Njd4IF2=	M1nkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR5	NFzRPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\IW\|Ztd2eJSUWwQU03NjJ4IF2=	Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR8	M1XtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXsc4dIUTVyPT21Mlc{KE1?	NHu5NHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SKOV3	NUfIOpg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrBT4ttd2eJSUWwQU03NjV{IF2=	NFnIcXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
RXF631L	M{L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnuXnRtd2eJSUWwQU03Njh6IF2=	NIH6OpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
ACHN	M3jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDB[HJbdG:pR1m1NF0uPi5yNzDN	M3zuN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
St-4	NYfLO5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnFT3pGdG:pR1m1NF0uPS53NjDN	MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN1	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIH4d4ttd2eJSUWwQU04NjB6IF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN7	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\v[\|Ntd2eJSUWwQU03NjVyIF2=	M1;GRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN28	NEPwfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjMcI9oT0l3ME2tOU42OiCP	M3TjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN45	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmq2cI9oT0l3ME2tOk42PSCP	M3zRRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN74	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfFOY5td2eJSUWwQU03NjB{IF2=	MknwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DU145	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFL2U3ltd2eJSUWwQU02Njh3IF2=	NFPkSoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
PC3	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYK4XJRJdG:pR1m1NF0uPi54NjDN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
ES5	NYT4ZoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fqXmlEPTB;NUCuNlEhdk1?	NHTsN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HH	NXfpRlFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFzMT6wPEBvVQ>?	MnqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MHH-PREB-1	MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjIfW0{UUN3ME2xNVQvOyCwTR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1770	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;j[JNKSzVyPUGyN{45PiCwTR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuO9	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XrT2lEPTB;MkC2MlAzKG6P	NGm4V409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HAL-01	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3oVnRKSzVyPUKwOk44OyCwTR?=	NYnXO5Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NOS-1	M3TNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr6SGlKSzVyPUKxNU45OiCwTR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HGC-27	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFraXFhKSzVyPUKxNk42PyCwTR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB69	NV3nSVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvkW5B1UUN3ME2yOFUvOjdibl2=	NHPIXXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RS4-11	MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJ4MT63OkBvVQ>?	NXPkSJF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DOK	M2DrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTNyMT63JI5O	M4\rTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB2241-RCC	NFm0fVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEGwR\|lKSzVyPUOwN{45PCCwTR?=	NIHZVmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H1623	NVHDboxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1znPWlEPTB;M{C0MlA5KG6P	Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
YH-13	NXn5PGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;PTWM2OD1\|MESuN\|Ihdk1?	NITtPVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BPH-1	NXPDNZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jTbmlEPTB;M{G0JI5O	Ml\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
AN3-CA	NUj6[IhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTQUG9KSzVyPUO0NE4{PyCwTR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ES7	NIDTeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr1OY9KSzVyPUO0NU46QSCwTR?=	Mn;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MDA-MB-175-VII	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXCSWxKSzVyPUO1Nk46OiCwTR?=	NEDuT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GAMG	NU[4TXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mli3TWM2OD1\|N{CuPFUhdk1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CHL-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rHfmlEPTB;M{e4MlY2KG6P	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NB7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rDWWlEPTB;M{i5Mlg{KG6P	M4GxdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MFE-280	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[4XGlEPTB;NEG4MlIhdk1?	NYPDTFRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HL-60	NH7kdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\yVFhKSzVyPUSyOU44PSCwTR?=	M4HzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
GCIY	NUTHTmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;XU2lEPTB;NEOzMlghdk1?	NHzkblE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-361	M4HPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTZcoZtUUN3ME20N\|kvOTNibl2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LXF-289	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\KTWM2OD12NEiuNlchdk1?	MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NBsusSR	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XrZ2lEPTB;NEi4Mlg2KG6P	Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KU-19-19	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvyfW5KSzVyPUWxOk4xPyCwTR?=	NEXNWm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A204	NG\tbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTV{Mj6zN{BvVQ>?	NWCyU2RXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfhTWM2OD13MkKuPVMhdk1?	NInXOVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COLO-684	NYnYNGp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn1UmN[UUN3ME21NlMvOTFibl2=	NXrOd3dDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
PA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknQTWM2OD13M{KuOFEhdk1?	NH3CfHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MG-63	NHjkWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmriTWM2OD13NEGuNVEhdk1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BHT-101	NEnyPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH33Tm5KSzVyPUW0OE46PCCwTR?=	M1u1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NKM-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mln2TWM2OD13OUOuNFkhdk1?	M{PjXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
T47D	NXz5U4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[3TWM2OD13OUeuOVYhdk1?	NH\kSWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MOLT-4	M4i1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ywWmlEPTB;NkKzMlYzKG6P	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
IGROV-1	NGrjUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPTR3FKSzVyPU[zOE4{OSCwTR?=	M3jh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES4	M3Hid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknqTWM2OD14M{muOVQhdk1?	NVzaZnlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HuO-3N1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTZ2Mj6zPEBvVQ>?	Mn3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NEC8	M4S3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUX2doM{UUN3ME22OVMvPTdibl2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HO-1-N-1	NVnQSY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\tbGlEPTB;NkW5MlE4KG6P	M2D3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EPCL-272H	NFnrUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTZ6Nz6yNUBvVQ>?	NGLycmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
D-263MG	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\0TWM2OD15MUiuNUBvVQ>?	NV[zS\|RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MV-4-11	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j0U2lEPTB;N{K0MlMyKG6P	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-NEP-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLTTWM2OD15MkWuPVQhdk1?	NXnIdXBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW872	NH7EWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrLSWRTUUN3ME23NlcvQDlibl2=	MnXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
P30-OHK	Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHqdGtNUUN3ME23N\|AvPzFibl2=	M{fMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OMC-1	M1W4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTd3MT6wPUBvVQ>?	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LoVo	NIfPcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfXeJVKSzVyPUe3O{46KG6P	NVjrSXdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTd7Nj6zOEBvVQ>?	NXfqPWpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
L-363	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVf3eo5LUUN3ME23PVgvPDJibl2=	NXHGSWZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ES8	NV32fXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnGN5lQUUN3ME24NVAvPTJibl2=	Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
697	NWmyOYZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7KdIY6UUN3ME24N\|EvPTVibl2=	NFvEbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HSC-3	M3;QPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPBTWM2OD16M{muOVQhdk1?	NGLpbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
H4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLxdFNKSzVyPUi1NE45PSCwTR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
QIMR-WIL	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTh4NT6yJI5O	Mk\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OAW-42	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW4TWM2OD16N{KuNVkhdk1?	NH7BRpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MCF7	M3r3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HISWlEPTB;OEm4MlU6KG6P	M3f2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SCC-25	M4PlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTLcGJqUUN3ME25NVQvOTlibl2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1563	NWfNO5N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHTXY1KSzVyPUmxOU46QSCwTR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OVCAR-5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml34TWM2OD17NECuNVchdk1?	MorLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HDLM-2	NFHU[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrhTo1KSzVyPUm0PU4zKG6P	NVTTTmRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NB5	NYXLdlhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nN[mlEPTB;OUW2MlYhdk1?	NXHQb\|BQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H292	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfuV4U5UUN3ME25O\|QvOzJibl2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A101D	M3X3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PP[WlEPTB;OUmwMlE6KG6P	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1648	M2DhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDoeIRKSzVyPUm5PE42OSCwTR?=	NH;CWIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EKVX	NYXLUY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nFc2lEPTB;MT6wNVI6KM7:TR?=	NFfz[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW1710	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwMESyN\|Mh\|ryP	NXToe3hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
WM-115	NX;4bXhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrUfHRYUUN3ME2xMlA3PjV4IN88US=>	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-54	NEntfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIf3ZXhKSzVyPUGuNFcxQDFizszN	NF7qSGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TGBC24TKB	NIjLVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TkXGlEPTB;MT6wPFA1PSEQvF2=	M{\WZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H520	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnRTnJmUUN3ME2xMlA5QTZ5IN88US=>	NY\6SmNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
D-423MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP4TWM2OD1zLkC5PVYzKM7:TR?=	M4jwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BFTC-905	NYXkbm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mon2TWM2OD1zLkGzOFQ6KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HT	NVHYdXVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELDN3lKSzVyPUGuNVM1PzhizszN	NIrwSlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CTB-1	NV75U\|A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwMUSyPVMh\|ryP	MnTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Hs-578-T	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwMUm1OlUh\|ryP	Mn7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuH-7	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XqWWlEPTB;MT6yNFk1QSEQvF2=	NVXYbGZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB996-RCC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwMkKxO\|ch\|ryP	MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-270	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXBTWM2OD1zLkK5O\|M1KM7:TR?=	NXTtVVZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A4-Fuk	NV7vOJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFG0fWFKSzVyPUGuNlk6QTNizszN	NIiwfmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A498	NVW5S\|dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe1XVl2UUN3ME2xMlMxPDd2IN88US=>	M4K0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-1	NFjGSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjuTWM2OD1zLkOwOlc6KM7:TR?=	M1;kcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AU565	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TmZWlEPTB;MT6zNVg3OyEQvF2=	MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Saos-2	NXPufGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFqyR\|ZKSzVyPUGuN\|MzODVizszN	NWTzT\|R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A549	M4XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PzVWlEPTB;MT6zPVk4KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BFTC-909	NX;sXJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXR[lg3UUN3ME2xMlQ{OzB3IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MDA-MB-415	M1LLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\iTWM2OD1zLkS4OlkzKM7:TR?=	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
639-V	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\VTWM2OD1zLkWwNlQ2KM7:TR?=	M2W2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A704	NGLhPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7ZeJpLUUN3ME2xMlUxPzh3IN88US=>	NHLGU\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PANC-03-27	NVP0SXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFwNUG0NFgh\|ryP	M{XsNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-28	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvSXHJIUUN3ME2xMlU3ODh3IN88US=>	M3LYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFwNkC3OFYh\|ryP	NX71e4FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HuP-T4	M37jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDFTWM2OD1zLk[wO\|c5KM7:TR?=	M2\DWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\4OI9KSzVyPUGuOlEzPyEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EFM-19	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPIZ3RTUUN3ME2xMlYyQDFizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
G-401	NIGzSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXNSmVrUUN3ME2xMlYzOTZ2IN88US=>	NIqwWZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
D-566MG	NIrUOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFwNkK1N{DPxE1?	M2HDSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
JVM-3	M4CwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTRc4VKSzVyPUGuOlQ5PzVizszN	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TK10	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DVcmlEPTB;MT62O\|A5OyEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BT-20	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfp[IhKSzVyPUGuOlg6ODJizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EGI-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnGPWtKSzVyPUGuPFQ4ODFizszN	NWDQVVdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-16	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwOEWxPFIh\|ryP	NUDtZ45IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2228	NFjTflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fzdWlEPTB;MT64OVIxOyEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BB49-HNC	NFXQbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHGTWM2OD1zLki4OlkzKM7:TR?=	NW\qOmtNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
G-402	M4H0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fJUWlEPTB;MT64PVc6PyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H526	NES3WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjKd4xKSzVyPUGuPVE{QSEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ME-180	NFHFWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjPcGtKSzVyPUGuPVM1PzdizszN	MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PFSK-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\jd5hKSzVyPUGuPVQ1PThizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TYK-nu	NWnLbFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwOUW4NlMh\|ryP	NUPuVYR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HOS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXDdVlVUUN3ME2xMlk4QTR6IN88US=>	MmXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
T98G	M4OyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFwOUmwNFYh\|ryP	NEfJXoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MES-1	NVjkZo94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwMEGzN\|Ih\|ryP	M{XnOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SNB75	M1PEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWmyfVQzUUN3ME2yMlAyPTRzIN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LAMA-84	M17tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLKS25KSzVyPUKuNFI3QDlizszN	MofvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-39	NUfxW\|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C4WmlEPTB;Mj6wN\|I5KM7:TR?=	NELtVWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LOXIMVI	M3TKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHwNZBqUUN3ME2yMlA1ODh2IN88US=>	M{HzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NH-12	M3z4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{H2cmlEPTB;Mj6wOVQzPCEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1048	NVizUWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX4TWM2OD1{LkGwOVIh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KS-1	NXfUfIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37nPGlEPTB;Mj6xNVAxOSEQvF2=	NF:0ZZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-N87	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXX2[G4zUUN3ME2yMlE{Ozh2IN88US=>	NV;LUmFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CHP-212	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjPXmpKSzVyPUKuNVg1PDJizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCC1419	NXLQ[Y9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH5SphvUUN3ME2yMlIyOTF3IN88US=>	Ml7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES1	M3yxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJwMkGzNlYh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2030	NGrv[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TYTmlEPTB;Mj6yOFEzOyEQvF2=	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EW-22	NUTUS5RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT0TWM2OD1{LkK1NFY4KM7:TR?=	NGLJOng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A431	NYWzSoozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInJXmpKSzVyPUKuNlc{PTRizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SF126	M17I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHpTlNKSzVyPUKuN\|A3OjVizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SF295	NIjoW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2OwO2lEPTB;Mj6zNVUzPCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-502MG	NUDM[4FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJwM{K0OlEh\|ryP	M2q2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC2157	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJwM{K5Nlch\|ryP	NU[0elMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
D-283MED	NEHUVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwM{W5NlYh\|ryP	MojiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SNU-423	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS5SGtGUUN3ME2yMlQxOTdzIN88US=>	NUSxUolMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-LU-1	NXvaeVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mof0TWM2OD1{LkS0OVg3KM7:TR?=	MkHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
22RV1	NV3Zb3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXuO\|lxUUN3ME2yMlQ2PjF5IN88US=>	MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW1088	NVjZRWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\PUWlEPTB;Mj60PVIyOyEQvF2=	NILTcZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn3VIpKSzVyPUKuOFkzPTlizszN	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1666	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJwNUGxNFQh\|ryP	Mlj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EM-2	NIHmTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi0TWM2OD1{LkWxNVY6KM7:TR?=	MnjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SNU-449	NVvZdmR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfaOZJ{UUN3ME2yMlU4ODF2IN88US=>	M37nXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
786-0	NULHd3kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqxZnVKSzVyPUKuOVkzOzhizszN	M1LNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SKG-IIIa	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rUU2lEPTB;Mj62OVk{QSEQvF2=	NITnOmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MEL-HO	M2LCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;pcYdKSzVyPUKuOlc3OzRizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LCLC-97TM1	NIL6eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJwNkmyOlch\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MKN7	M1zUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\zZnhKSzVyPUKuO\|A4PTRizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
5637	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPUTWM2OD1{LkexNFM2KM7:TR?=	M37zfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HOP-92	MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LCNmlEPTB;Mj63OFcyPyEQvF2=	M{n5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MDA-MB-157	M4f0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\le5gzUUN3ME2yMlgzODJ\|IN88US=>	M{C0XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NB12	NGT1SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTJwOES5NVQh\|ryP	NIrZcWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DMS-273	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJwOE[0O{DPxE1?	M3\SZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC70	MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlr3TWM2OD1{Lki2OVg6KM7:TR?=	NVjpc2luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
YKG-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD0TphKSzVyPUOuNFM4QDdizszN	Mn35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H28	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrkZYJGUUN3ME2zMlA2OjlzIN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HN	NHPnR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnTTWM2OD1\|LkC2OlM3KM7:TR?=	NIr3Ro49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT-1080	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DH[WlEPTB;Mz6wPFYxPiEQvF2=	M4TRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HPAF-II	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrmTWM2OD1\|LkGwNFY5KM7:TR?=	NF;GdGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
U-2-OS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTiTWM2OD1\|LkGzO\|gzKM7:TR?=	NYfDXXBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SNU-387	M2DiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3DTWM2OD1\|LkG2N\|Y1KM7:TR?=	NWf4fWpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Becker	NFHW[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNwMU[4NFgh\|ryP	M3TiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BHY	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\s[WlEPTB;Mz6yOVU4OSEQvF2=	NXnLNWVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HTC-C3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTNwMkmzOVIh\|ryP	NWTqd4NoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
M14	NHPCNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PoZmlEPTB;Mz6zNFY3OyEQvF2=	NFSyZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COR-L23	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjEZ4xUUUN3ME2zMlM4Ojd7IN88US=>	NXzQWWhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
C32	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj6TWM2OD1\|LkSxOVA5KM7:TR?=	NVTCT45JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Mewo	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXJbpRKSzVyPUOuOFIyQDJizszN	NFrhfW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TE-8	NVTsWJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PYUmlEPTB;Mz60PFI2QSEQvF2=	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-2650	NFnJXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrPe4JEUUN3ME2zMlYxPjN5IN88US=>	Mo\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
AGS	M3m4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELOfmJKSzVyPUOuOlI1PjRizszN	MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MZ2-MEL	NFnSdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTNwNk[xN\|gh\|ryP	NXX5VoVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Calu-3	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDKfmpiUUN3ME2zMlcyOjh5IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SJSA-1	NGTmeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTNwN{GzNVUh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW962	M4f2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHCcI1OUUN3ME2zMlczPjN4IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PC-14	M{\LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFftflNKSzVyPUOuO\|MzOjJizszN	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW1573	NYq2NnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnr6TWM2OD1\|Lke1N\|Q5KM7:TR?=	MnnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
769-P	M2jUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XBZWlEPTB;Mz64Nlc1OyEQvF2=	NEO2WGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KNS-62	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTNwOUKzN\|gh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H747	NIPvSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPuTWM2OD12LkC1OlM5KM7:TR?=	M4PjcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LN-405	M1L0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLwNYg3UUN3ME20MlE2PzJ6IN88US=>	M1foNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OVCAR-8	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTFTWM2OD12LkKyOVQ{KM7:TR?=	NIj1d\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DMS-114	NF23ZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jVe2lEPTB;ND6yN\|g6OSEQvF2=	MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2126	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkK0TWM2OD12LkK0OVU5KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TCCSUP	MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTRwMkS3PFgh\|ryP	NYjIcXZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-N-FI	NWD0Uo9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DzOmlEPTB;ND6yOVM{OiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCE-4	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTRwMkexPVch\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DK-MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknETWM2OD12LkOwN\|kh\|ryP	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RO82-W-1	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK4foNiUUN3ME20MlMzPTh2IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A2780	M37ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zVO2lEPTB;ND6zOlY5OiEQvF2=	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ETK-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrmfVB4UUN3ME20MlM4ODV{IN88US=>	NVryflZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
FADU	NHTqWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTibIJjUUN3ME20MlM4PDZ5IN88US=>	NHfFXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-12T	NVSzPG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEj5SZdKSzVyPUSuOFE1OTNizszN	NGXKTlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
647-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTRwNESwNlIh\|ryP	NHPEUXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TGBC1TKB	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7O[oJKSzVyPUSuOFUyOTNizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LU-99A	M3v0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;IcmlEPTB;ND60OlA3KM7:TR?=	MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-33	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;0R\|dKSzVyPUSuOVI1PTZizszN	NVrsTpRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LU-134-A	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTRwNUK3OFUh\|ryP	NV\YTHN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1355	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRwNUWxOFYh\|ryP	M{fIdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RPMI-7951	Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTRwNUewNFIh\|ryP	M2XUOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TE-1	NWLJdlFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDWTWM2OD12Lk[2NVQ{KM7:TR?=	NYmwNWJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OE33	NXvZe2hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnL3TWM2OD12LkewOVEyKM7:TR?=	MknHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-51	NXPCcYhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTRwN{GwPFIh\|ryP	NITKcFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW1783	M1TVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvkV5E2UUN3ME20Mlc2OzB6IN88US=>	M1nZNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BT-474	NUDyRWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fOW2lEPTB;ND63OlM5PCEQvF2=	MnTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-520	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTRwOEezPVIh\|ryP	NFuzVGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
8-MG-BA	NV7pZWR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIK0NHNKSzVyPUSuPFg2PTdizszN	NIrlUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
IA-LM	M3e0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W3VWlEPTB;ND65PVQ{PSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW954	NHv6V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTMTWM2OD12Lkm5OFQ{KM7:TR?=	NWf1SVh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RPMI-8226	M4i1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTVwMEW0OlEh\|ryP	M2PmNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MKN1	M3jRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTVwMEe5Nlch\|ryP	M2LsTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A375	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXmSHVKSzVyPUWuNFkzPTZizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
8305C	NHfzXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTVwMEm4PFch\|ryP	Mke3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-62	M4jSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4T4fGlEPTB;NT6xPFI2QSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrBZoJKSzVyPUWuNlI4PDRizszN	NHPhV4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
OC-314	NWL2cW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3ndld7UUN3ME21MlM4PDR2IN88US=>	NGrST4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PSN1	NY\qeGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn4cFluUUN3ME21MlM5Ojh4IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GR-ST	M2H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mne0TWM2OD13LkO4N\|IzKM7:TR?=	MomxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	M2f5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrFWZVKSzVyPUWuOFAyKM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1092	NVrM[Fg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXaW5pQUUN3ME21MlQyOTR6IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SCC-4	NVz0cZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELoVoFKSzVyPUWuOFE{PTVizszN	NVzvUXZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TE-6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvSNYpVUUN3ME21MlQyQDF4IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DOHH-2	NWruN2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPvR21iUUN3ME21MlQzOjR6IN88US=>	Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW684	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPONmlKSzVyPUWuOlY{QDVizszN	NFzzcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CP50-MEL-B	NWnWN5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPNTWM2OD13Lk[4Olg1KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
UM-UC-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwN{KyN\|Eh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LC-2-ad	NVX0V4NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\2NGxKSzVyPUWuO\|gzPTFizszN	NFLMRmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PC-3	NXXVcGloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33SfGlEPTB;NT65NVYyPSEQvF2=	M1L1eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAN	NV3pUo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTVwOUK4NkDPxE1?	NYnkcXV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ESS-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTVwOUe4Olkh\|ryP	NFjUV289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ATN-1	M2C1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml:xTWM2OD14LkC1OVY5KM7:TR?=	M4DENFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BxPC-3	M3T2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLkTWM2OD14LkC4NlE6KM7:TR?=	M4f6T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KYSE-150	NHywbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7ufnN[UUN3ME22MlEzPDd4IN88US=>	MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-8866	NYix[JR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYC0OnA5UUN3ME22MlE6OTZ\|IN88US=>	MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW780	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjteoR2UUN3ME22MlIxPDJizszN	NVPOTY9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A388	NInScHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTZwMkOxNVUh\|ryP	MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1437	NV7SRW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXuNJFHUUN3ME22MlI1ODd\|IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1755	NGjTOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTZwM{[2NVIh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LS-123	M2fWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPFXZBKSzVyPU[uOFA2OjFizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CaR-1	NEHNbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTZwNE[zO\|Mh\|ryP	NWXabVBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RT-112	NXzFdY02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XwcmlEPTB;Nj62NFM{QCEQvF2=	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CGT	NXXw[YV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjlWYJqUUN3ME22Mlc{PjhzIN88US=>	NYLLUmNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW626	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;ETWM2OD14LkezPVQ3KM7:TR?=	M1\lZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AsPC-1	NGfkOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTZwN{S1NFch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SBC-5	NVHvSXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFq3S3BKSzVyPU[uPVczQTdizszN	M1HpfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SF539	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTXN\|E6UUN3ME22Mlk6OzN\|IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TI-73	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTdwME[yPFUh\|ryP	M3fMd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MHH-ES-1	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\tN3Z3UUN3ME23MlA4PzZ{IN88US=>	NHjvepM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KYSE-510	NIHKcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK0RYJKSzVyPUeuNFg1OzJizszN	M4LuN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EW-1	M2HJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PVeWlEPTB;Nz6zOlk6PiEQvF2=	M{nLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-OV-3	NY\ueGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTdwM{m0N\|Ih\|ryP	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MC-IXC	NVTQcFZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTdwNEG5O\|Ih\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HSC-2	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDmT2Y4UUN3ME23MlQzPzB3IN88US=>	M3L5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2342	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlm3TWM2OD15LkWxOFkh\|ryP	NVHkPGlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1792	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHVe5pKSzVyPUeuOVE4OTFizszN	M3zaTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT-1376	NUfV[IlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzU[Ig1UUN3ME23Mlg4Pzd6IN88US=>	NU\TTVNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-13	NIS3WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7STWM2OD15Lki5PVc4KM7:TR?=	M4LUbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
no-11	M4LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LWUWlEPTB;Nz65NFE4PCEQvF2=	MnTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Daoy	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjsTWM2OD15Lkm0N\|IyKM7:TR?=	MkTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-800	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRThwMESxOlIh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GB-1	M36yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DhR2lEPTB;OD6wOlU3PSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SJRH30	NVHsPIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;VW2pOUUN3ME24MlE2QDd6IN88US=>	MlfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2291	NGjlfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7jU2xHUUN3ME24MlI6OTh5IN88US=>	NEXo[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
J82	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP2e\|hKSzVyPUiuNlk1QTFizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H596	NV3OeHc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXRO4RNUUN3ME24MlMyPDV\|IN88US=>	M{n6UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	NGjVcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7SSlZKSzVyPUiuN\|Q5PTZizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RH-18	NVu0THZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[2TWM2OD16LkO1NFQ3KM7:TR?=	NXPFVZdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW48	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\1TWM2OD16LkW5OFU{KM7:TR?=	NGToW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RD	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;5TWM2OD16LkW5N\|kyKM7:TR?=	M4DFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MS-1	NY\NNXprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRThwNkGzPFch\|ryP	M1XGRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES6	NXX3TllRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPmWohmUUN3ME24Mlc{OTF7IN88US=>	Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-12	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nxTmlEPTB;OD63O\|UxPSEQvF2=	MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DBTRG-05MG	NU\RcGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRThwOUGyNVch\|ryP	NV\3emxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KINGS-1	NH\obYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHJdHFjUUN3ME24MlkzQTN6IN88US=>	M{PH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HLE	NG\OTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRThwOUO3PFUh\|ryP	MoK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MHH-NB-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnufGFKSzVyPUmuNFE5OzlizszN	NFizb2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
U-87-MG	NFrJdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkThTWM2OD17LkK0N\|IyKM7:TR?=	NEnOTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MN-60	M1vmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\Dc\|liUUN3ME25MlI1PTR{IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SAS	NWnieWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPjRYNKSzVyPUmuNlU2QDFizszN	NH\ydpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H446	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3xTWM2OD17LkO2NUDPxE1?	NGnh[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
C-33-A	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PKeGlEPTB;OT60N\|k5QCEQvF2=	NHjOS2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RXF393	M2\xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXm0dWMzUUN3ME25MlQ4ODB{IN88US=>	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CGTH-W-1	M3;rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTlwNEmzPFQh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RCM-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13tUWlEPTB;OT62N\|gxOSEQvF2=	NH3pTHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SN12C	NWLlTZlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXYZotUUUN3ME25MlY2OzN6IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFqwVJBKSzVyPUmuO\|AxODlizszN	NFXkfVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EFO-21	M33MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTlwN{ezPFIh\|ryP	NXHG[3B2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-70	M4S3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnrTWM2OD17Lki4NFEyKM7:TR?=	M4LHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-247MG	NWHz[49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoT6TWM2OD1zMD6wOVY5KM7:TR?=	NWjzNHBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MPP-89	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\1XnpLUUN3ME2xNE4xQTR4IN88US=>	NIeyOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RVH-421	M4n0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3KNYpKSzVyPUGwMlE2ODVizszN	NWK0bHQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H460	M4O2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;iZ5RKSzVyPUGwMlI5ODZizszN	M12zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NOMO-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3oVFcxUUN3ME2xNE4{PTN{IN88US=>	M4q1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DEL	NXjuWmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFyLkO3PVQh\|ryP	NVT4e\|I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HT55	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFyLk[yNFUh\|ryP	NXnySpA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MC116	NYTYb\|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;TTWM2OD1zMD62OlU2KM7:TR?=	M1vDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BB30-HNC	MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTFyLk[2PUDPxE1?	MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DJM-1	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDRTWM2OD1zMD62PVQ6KM7:TR?=	M3vSVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ZR-75-30	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFyLkm0OFEh\|ryP	M1fud\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
U-118-MG	Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1H0bGlEPTB;MUCuPVg6PiEQvF2=	MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MSTO-211H	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFzLkC3NVYh\|ryP	MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW837	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[yTWM2OD1zMT6wPVQ6KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuCCT1	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfzNGJKSzVyPUGxMlEzQDFizszN	Mo\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RCC10RGB	NHHDVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFzLkGzOUDPxE1?	Moi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NMC-G1	NILTXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnFUlBKSzVyPUGxMlE1QTNizszN	M3n0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H650	NEH6Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFzLkO3PVQh\|ryP	M1X4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HEC-1	NIHpXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfBVFhLUUN3ME2xNU41OzJ6IN88US=>	NXr0Zng6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DU-4475	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTFzLkezPVMh\|ryP	NIW3V489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DSH1	NFThOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFzLke2NFYh\|ryP	M1jselxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC1569	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPGTWM2OD1zMT63Olc5KM7:TR?=	M17COlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC1187	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFzLki1PFgh\|ryP	M2fnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EW-11	M{O0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHv[5BHUUN3ME2xNU46PDd2IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LB2518-MEL	NYPaOFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFH6OJpKSzVyPUGyMlA2QSEQvF2=	NE\HelE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KALS-1	NHHzbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fUeGlEPTB;MUKuPFU2OyEQvF2=	M1jlTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
8505C	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkj0TWM2OD1zMj64PFUh\|ryP	NXHYVZBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-N-DZ	M2DkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTF\|LkC0OVMh\|ryP	NXvVNFVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CHP-134	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nncWlEPTB;MUOuNVE2QCEQvF2=	NWnZWII{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HCE-T	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrZTWM2OD1zMz6yN\|Y1KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LB-831-BLC	NHrGbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPqSItxUUN3ME2xN{43OjR4IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OVCAR-4	NUfRVGlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGn2[mNKSzVyPUGzMlY2OjRizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW756	NGq5c4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETwR4xKSzVyPUGzMlczPDZizszN	NGL3c2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
OCUB-M	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDx[pJMUUN3ME2xN{45OTV4IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW982	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF\|LkiyO\|Yh\|ryP	M2HYZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfBbmFKSzVyPUGzMlg{QDRizszN	Mk\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
H-EMC-SS	NFPqZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\TTGlEPTB;MUOuPVE{QSEQvF2=	NWTJRXNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfQWXVjUUN3ME2xOE4xODF3IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CAKI-1	M3vMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7OPGVKSzVyPUG0MlAyOzJizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GI-1	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvHTWM2OD1zND6wOlU5KM7:TR?=	NYnZW3FMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Ca9-22	NWLXW21pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEL2PINKSzVyPUG0MlYxPTRizszN	NY\idmg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TE-5	M1XJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz2TWM2OD1zND63NlA5KM7:TR?=	M{n3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EFO-27	M1PUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDHZ4JoUUN3ME2xOE44PjJ{IN88US=>	NGnIco49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-72	M{nMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjMNo9sUUN3ME2xOE44Pzh\|IN88US=>	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GP5d	M1HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF3LkC0O\|Qh\|ryP	MknnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAS-1	NH7yeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTF3LkC2OkDPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A2058	NF\lXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Gx[WlEPTB;MUWuOVY{QCEQvF2=	M1juTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
PANC-08-13	M{jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L1emlEPTB;MUWuOlg2QSEQvF2=	M2j4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Detroit562	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;k[FF6UUN3ME2xOU46OTN7IN88US=>	NVLLNGlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
PANC-10-05	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\T[2lEPTB;MU[uNFgzOSEQvF2=	M1fBeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KOSC-2	NETxSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFK4W2lKSzVyPUG2MlEyOjVizszN	M4fqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
GT3TKB	NH;DeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTF4LkG5PFEh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KM-H2	M360dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTF4LkO2OFYh\|ryP	NYrJVlVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB771-HNC	NYfY[Yl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojYTWM2OD1zNj60OFIzKM7:TR?=	NFvhPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SF268	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zQSGlEPTB;MU[uOFUzKM7:TR?=	NU\uXHpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OE19	M3zNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfad4pKSzVyPUG2MlUzPCEQvF2=	NYjW[WlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MLMA	M1HmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF4LkW1O\|Eh\|ryP	NYDaOZZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MDA-MB-231	M3TGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XEXWlEPTB;MU[uO\|E{PiEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TGW	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzMcVdKSzVyPUG2MlgyODJizszN	NHvtZoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-453	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;xdWZtUUN3ME2xO{4xODB\|IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SNU-C2B	NGjyTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVK0UXhIUUN3ME2xO{4xOjN5IN88US=>	NF7wcHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A427	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDveVJKSzVyPUG3MlI{OzRizszN	NVfoTlh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-MEL-2	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4C0SWlEPTB;MUeuN\|IyOyEQvF2=	NGnOeoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KURAMOCHI	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jWS2lEPTB;MUeuN\|g6PyEQvF2=	Mm\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
IST-MEL1	NGjQPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHKUGxCUUN3ME2xO{46OTh{IN88US=>	NIfkO3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H1793	M3\Db2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnYcXhKSzVyPUG4MlE2QDFizszN	NHLsdIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HCC1395	M3rNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF6LkW2NVEh\|ryP	M3HRNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NUGC-3	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jUN2lEPTB;MUiuOlU5PCEQvF2=	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BB65-RCC	M1;vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HTd2lEPTB;MUiuOlY6KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RMG-I	NXfiRollT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTTe2JKSzVyPUG4Mlc{QDJizszN	NI\6cHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LS-513	NEfBcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXNXphKSzVyPUG4MlkzOjhizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MFM-223	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HQXGlEPTB;MUmuNFcyPiEQvF2=	NVPPS5JWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H727	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzQOGprUUN3ME2xPU4{Ojl3IN88US=>	NYTmV5VURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KP-4	NEDsfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7PTWM2OD1zOT64OVMyKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB13	M4jGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF7Lki4N\|kh\|ryP	NVLoO4lsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
UACC-893	NH70boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfRTWM2OD1zOT65O\|U4KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HT-1197	NXX0ToRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfYe2xVUUN3ME2yNE4zQTV6IN88US=>	M2rkZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2029	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnYTWM2OD1{MD6zNlY3KM7:TR?=	MkLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GI-ME-N	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlniTWM2OD1{MD6zN\|c{KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OVCAR-3	M1\zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTJyLkW4NlIh\|ryP	M{ezRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HD-MY-Z	NHH6eoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jwd2lEPTB;MkGuN\|Y6PiEQvF2=	M4XFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTJzLk[3NlIh\|ryP	MoTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SCH	NHr6bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr1[oRKSzVyPUKyMlQ6PiEQvF2=	MnfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KARPAS-299	NGjVVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnY[5FNUUN3ME2yN{4{QDh5IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1650	M{X6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJ\|LkmyOFEh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ACHN	NGDvPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPUTWM2OD1{ND60OlU3KM7:TR?=	M4TMNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
M059J	M2m0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvIVo5KSzVyPUK0MlU3OzRizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
AM-38	NFz5Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1uxbGlEPTB;MkWuOFgyKM7:TR?=	Mnn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KG-1	M1vBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf5bpFiUUN3ME2yOU42PDl2IN88US=>	NHfWcIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COLO-824	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfW[XNKSzVyPUK1MlU2QTlizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1155	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rhSWlEPTB;MkWuOVg1PyEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H441	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PIcWlEPTB;MkWuO\|Q3PSEQvF2=	M3v0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ4LkOwNlch\|ryP	Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
JEG-3	NVfn[IxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjjT29yUUN3ME2yOk43QDB3IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RKO	NH60dWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\sVItKSzVyPUK2Mlc3OzJizszN	NXrBbZRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-85-1	NXvHd4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjIe4gyUUN3ME2yO{4zOTF6IN88US=>	NUTUUWZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-120	NFXWWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJ5Lk[5NVQh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2452	NYLlN3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJ5Lke3NVYh\|ryP	M2S4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1395	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ntdWlEPTB;MkeuO\|g{OyEQvF2=	NXLaNoZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-450	M{jLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnYTWM2OD1{Nz65PFYzKM7:TR?=	NHPEZW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
S-117	M1rKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\xXWlEPTB;MkmuN\|g2PyEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW13	M4n1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1voemlEPTB;MkmuPFUyQSEQvF2=	NV;4fYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ES3	NV:2[YhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O4PWlEPTB;M{CuN\|c{OyEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCT-116	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\Zd2lEPTB;M{CuOVU2PCEQvF2=	NWHEToV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1693	NEnIeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3LTWM2OD1\|MD61PVQzKM7:TR?=	MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
VM-CUB-1	NGfRWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfqRZZSUUN3ME2zNE43PDF\|IN88US=>	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2170	M2Gxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;FN2lEPTB;M{GuOVc5PCEQvF2=	M1HXeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ALL-PO	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\2WmlEPTB;M{GuPFQzQCEQvF2=	NVO0Wlk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H661	NFzl[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXwTWM2OD1\|Mj6wOlI{KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2347	NHTMWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{izeWlEPTB;M{KuOFg{PyEQvF2=	NHPKdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
FTC-133	NX;PU\|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\YTWM2OD1\|Mj63NFYh\|ryP	MmDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-829	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnqOZFKSzVyPUOzMlM1PjdizszN	MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GOTO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXJTWM2OD1\|Mz61NlU5KM7:TR?=	M{PoUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
YAPC	NFu5R\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPydWY{UUN3ME2zN{45OTV7IN88US=>	M{m0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LCLC-103H	NFvINYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnqxTWM2OD1\|ND6xOlI1KM7:TR?=	M1XpW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SiHa	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjETWM2OD1\|ND6zPFE4KM7:TR?=	NIHqSXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LK-2	NIXuWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3S1bWlEPTB;M{SuOVcxQCEQvF2=	NX;Fb4JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KP-N-YS	M1fzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzNcXJKSzVyPUO0MlczODJizszN	NVzWdG1YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTR[llqUUN3ME2zOU4yPzlizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KNS-81-FD	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTN3Lk[2N{DPxE1?	NYjoN4FERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SCC-9	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETDbndKSzVyPUO2MlcyPDZizszN	NWK3eXZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SH-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XDemlEPTB;M{[uO\|Mh\|ryP	NXS0dYh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HCC-1954	NYX2fW9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fhcWlEPTB;M{euNlczQSEQvF2=	M{PWUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BALL-1	NFTSNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jOdWlEPTB;M{euOVMyPiEQvF2=	MkLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BE-13	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTN5LkewNVgh\|ryP	NYfyeXpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
COLO-678	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnqfIVLUUN3ME2zO{46PDN5IN88US=>	M4C5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-3	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmKzTWM2OD1\|OD6yN\|k4KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OAW-28	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3BR25LUUN3ME2zPE43OzlizszN	NH3WO3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAMA-1	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTN6Lkm2PVEh\|ryP	M4n5cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
C2BBe1	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzjTWM2OD1\|OT64NVgh\|ryP	M3TGc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A3-KAW	MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2n6WWlEPTB;NECuN\|Y3OSEQvF2=	NYHX[WJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-MEL-24	NYTlUI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojQTWM2OD12MD61PVMyKM7:TR?=	NXXPcJhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-140	NIfCVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTRyLkexOlUh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MOLT-16	NGrROG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFO0bY9KSzVyPUSxMlE2OzZizszN	M1zrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CFPAC-1	NFjHOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\jTWM2OD12Mj61NlEyKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB14	NIPGb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf5TWM2OD12Mj63NFI4KM7:TR?=	Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-792	M1nl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFK1NVNKSzVyPUSyMlg6PjFizszN	NELXR209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RH-1	NHi3TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf6TWM2OD12Mz60PFM3KM7:TR?=	NWfCelNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H522	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlr5TWM2OD12ND6zOVY5KM7:TR?=	M1;VO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Ca-Ski	M3fhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrvSpFKSzVyPUS0MlgyOTRizszN	NGjNTpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KGN	NW\KZ2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTR6LkOwOlMh\|ryP	M4XIc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
UACC-62	M2rHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnQbpJKSzVyPUS4MlQxPzJizszN	NV\rN5J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H358	M{iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIizOFdKSzVyPUS5MlMxOThizszN	NFzTXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LS-411N	NXrjS5dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLNdYtKSzVyPUS5MlMyOThizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IST-MES1	M3vNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTR7LkW2NlUh\|ryP	NGewUWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)